Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Sanofi plans its mobile diabetes future

Next phase of iBGStar project will focus on wider connectivity

- PMLiVE

FDA investigates safety of Novartis’ MS drug

Agency to determine association between Gilenya and rare brain infection

- PMLiVE

FDA turns down Otsuka’s kidney disease candidate

Requests additional information for tolvaptan

Bayer symbol

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

Advances pharma company’s ambitions in cancer

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

- PMLiVE

Novartis orphan drug wins ‘breakthrough’ status from FDA

Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

Bayer symbol

Bayer moves closer to US approval of PAH drug riociguat

FDA panel votes unanimously in favour of hypertension treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links